NCT03230149View on ClinicalTrials.gov

Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy

CompletedOBSERVATIONAL

Enrollment

379

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

December 24, 2021

Study Completion Date

December 24, 2021

Conditions

Fabry Disease

Interventions

DIAGNOSTIC_TEST

Measurements of the alpha-GAL enzyme activity

Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.

Trial Locations (1)

94270

CHU de Bicêtre, UNSIV (neurovascular stroke unit), Le Kremlin-Bicêtre

All Listed Sponsors

collaborator

Shire International GmbH

UNKNOWN

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03230149 - Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy | Biotech Hunter | Biotech Hunter